

## Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

- XPOVIO® is the first and only approved XPO1 inhibitor in Thailand.
- XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO® in Indonesia with approval expected in the second half of 2024.
- XPOVIO® has been approved for health insurance coverage in the mainland of China, Australia, Singapore and South Korea.

Shanghai and Hong Kong, PRC, September 23, 2024 — Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Thailand Food and Drug Administration has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for two indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma(MM) who have received at least one prior therapy; and (2) in combination with dexamethasone for the treatment of adult patients with MM who have received at least four

prior therapies and whose disease is refractory to at least two

proteasome inhibitors, two immunomodulatory agents and an anti-

CD38 monoclonal antibody, and who have demonstrated disease

progression on the last therapy.

With a novel mechanism of action, XPOVIO® is the world's first approved

orally-available, selective XPO1 inhibitor, which has already been

approved in nine markets in APAC. This successful approval for XPOVIO®

in Thailand will introduce novel therapies to the clinical management of

patients with MM in Thailand, benefiting many patients and their

families in the country. To date, XPOVIO® has also been included in

national health insurance or reimbursement schemes in the mainland of

China, Australia, Singapore and South Korea.

The ASEAN region, with its steady economic growth and a population

exceeding 600 million, has become a significant potential market for

global biomedical development. The accelerating aging population in

ASEAN has increased the overall disease burden on patients and local

communities, leading to a growing demand for novel therapeutics.

Fulfilling its commitment to enhancing the health and well-being of the

ASEAN population, Antengene has successfully obtained NDA approvals

for XPOVIO® in Malaysia in August and very recently in Thailand, and

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室 Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China Tel: (86) 021 3250 1095 **漁車** 德琪医药

expects XPOVIO® to be approved in Indonesia in the second half of 2024.

Looking ahead, the company aims to introduce more innovative

medicines to the ASEAN market, bringing improved healthcare to more

patients in the region.

While bringing XPOVIO® to more APAC markets, Antengene is also

striving to expand the indications of XPOVIO®. Leveraging the drug's

novel mechanism of action, Antengene is currently developing multiple

combination regimens of XPOVIO® for the treatment of various

indications including myelofibrosis (MF), and endometrial cancer.

**About XPOVIO® (selinexor)** 

XPOVIO® is the world's first approved orally-available, selective inhibitor

of the nuclear export protein XPO1. It offers a novel mechanism of

action, synergistic effects in combination regimens, fast onset of

action, and durable responses.

By blocking the nuclear export protein XPO1, XPOVIO® can promote the

intranuclear accumulation and activation of tumor suppressor proteins

and growth regulating proteins, and down-regulate the levels of

multiple oncogenic proteins. XPOVIO® delivers its antitumor effects

through three mechanistic pathways: 1) exerting antitumor effects by

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室 Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China Tel: (86) 021 3250 1095



inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]).

## **About Antengene**

Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global

德琪医药

rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, and Australia.

**Forward-looking statements** 

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other



risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.